FDA Accepts sNDA for Darolutamide Plus ADT in mHSPC
The FDA has accepted a supplemental new drug application (sNDA) seeking expanded indication for darolutamide (Nubeqa) for use in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate …